

Technology Advisory Committee C Interests Register
Faricimab for treating diabetic macular oedema [ID3899]
Publication Date: 29/06/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Michael Chambers	Committee member	Direct - financial	<p>In 2020 Mr Chambers helped co-ordinate a training programme run by the University of Utrecht in Real World Evidence for Roche, but this did not involve any specific consideration of Roche products.</p> <p>In 2021-22, Mr Chambers participated in an advisory panel for Pfizer, manufacturer of a possible comparator therapy, but in an unrelated disease area (prostate cancer).</p>	N/A	25.05.2022	N/A	It was agreed his declaration would not prevent Mr Chambers from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee member	Direct - financial	Dr Nicholas has attended paid advisory boards with Roche, and with Novartis, manufacturer of a possible comparator therapy, but in an unrelated area (multiple sclerosis).	N/A	26.05.2022	N/A	It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor Richard Gale	Clinical expert	Direct – financial and non-financial	<p>Professor Gale has worked as a consultant for Novartis at advisory boards and has received sponsorship to attend educational events or for travel.</p> <p>He undertakes private practice and is a partner of Yorkshire Eye Specialists LLP.</p> <p>Professor Gale has undertaken clinical trials and research studies in the field of DMO, some funded by Novartis. He has also published about unmet needs in the management of DMO, although not in respect of faricimab.</p>	N/A	25.08.2021	N/A	It was agreed that his declarations would not prevent Professor Gale from providing expert advice to the committee.
Stephen Scowcroft	Patient expert	Direct – financial	Mr Scowcroft's employer, the Macular Society, receives financial support from a number of pharma companies. None of the companies have direct editorial input into Macular Society information or activities.	N/A	06.10.2021	N/A	It was agreed that his declaration would not prevent Mr Scowcroft from providing expert advice to the committee.